OEL Fastrac Catalog

Honey (CAS RN 8028-66-8) is a saccharic secretion gathered and stored by honeybees of the species Apis mellifera, Tetragonisca angustula, Scaptotrigona pectoralis, or Melipona beecheii. Honey consists essentially of different sugars, predominantly fructose and glucose as well as other substances such as organic acids, enzymes, and solid particles derived from honey collection. Enzymes in honey include invertase, glucose oxidase, catalase, and acid phosphorylase. Honey is a carbohydrate-rich syrup produced by bees, primarily from floral nectars. Honey is common in food and food products worldwide. Honey can be found in over-the-counter (OTC) cough and cold medications. Currently, there is a Food and Drug Administration (FDA)-approved dermal dressing containing honey used for the management of wounds and burns. Traditionally, honey has been used as an antibacterial, antiseptic, antiinflammatory, and apitherapeutic agent. Traditional Ayurvedic treatments utilize honey for cardiac pain, palpitations, and eye ailments

Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API).

Please note: Due to the complexity and amount of studies regarding this compound—a Natural Health Product—increased cost is charged.

Why do you need this OEL Fastrac monograph?

OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:

• The numerical OEL and control band assignment needed to determine the level of required engineering controls and personal protective equipment
• A listing of all cited references utilized in the derivation of the OEL and ADE
• An expert review and discussion with respect to the critical endpoints of concern, the rationale for the choice of endpoints, and dose that is to be used in the derivation of the ADE (PDE), as required by the EMA's Guideline on setting health-based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities

Benefits of OEL Fastrac monographs

• Fully documented. Over 20 pages in length, with calculations and cited references.
• Save time! Unsurpassed delivery with instant download.
• Save money. Similar documents cost 5-12 times as much.
• Stay current. Automatic notification of revisions.

How to order

To order an OEL monograph for Honey, just click the ADD TO CART button.

HBEL

If you're wondering about HBEL, we have something for you.